Introduction to Beike
Cell science supported by operational and quality systems.
Shenzhen Beike Biotechnology Co., Ltd. (“Beike Biotech”) was founded in July 2005 and is headquartered in Shenzhen. Company figures reported in January 2024 listed more than 740 employees, with over 40% working in technical R&D roles. Beike operates research, cell-processing and biobanking programmes with teams in China and international scientific collaborators.
The company reports management-system certifications covering quality (ISO 9001), environment (ISO 14001), occupational health and safety (ISO 45001), and information security (ISO 27001). Certification scope and current status should be confirmed for the specific facility or service under consideration.
Beike's operating model combines comprehensive cell banks with regional cell-preparation centres. This infrastructure supports research and partner programmes across several regions of China; the applicable quality, regulatory and release requirements are defined separately for each programme.
740+ Employees reported in Jan 2024
207 Patent applications reported in Jan 2024
100+ Papers reported in Jan 2024
AABB Accreditation for specified activities
Our history
Two decades of organisational development.
Beike was incorporated in Shenzhen in July 2005 after earlier research work by members of its founding team. Its activities subsequently expanded from cell processing and storage into research platforms, standards work and collaborations with medical institutions.
Earlier Beike websites reported patient, laboratory, funding and partner-hospital totals. Those historical figures described different periods and operating models, so they are not presented here as current facts. In 2010, Chinese Premier Wen Jiabao toured the company's Shenzhen facilities.
Today this international site presents Beike as a biotechnology and research organisation, not as a clinic. Any work involving human participants or clinical use must be assessed through the responsible medical institution and the applicable ethics, regulatory and quality frameworks.
Working principles
Principles for scientific and operational work.
01
Integrity
Communicating evidence, limitations and responsibilities clearly, including when the answer is uncertain.
02
Accountability
Daring to take responsibility — standing up in the face of difficulty, owning mistakes, and exhausting every method to find a way through.
03
Rigor
Continuous improvement in every link and every detail; details determine success or failure — meticulous, and right the first time.
04
Innovation
Technological and conceptual innovation as the driving force of progress and our enduring core competitiveness.
05
Care
Respect and spiritual communication between people; harmony begins with care, and care begins bit by bit.
06
Service
Professional, attentive service to customers; win-win, mutually beneficial service to partners. Service is our responsibility and our mission.
07
Teamwork
Combining complementary strengths through sharing, support and gratitude — turning “1+1” into more than 2.
08
Communication
Open communication that builds mutual trust, removes misunderstanding, and aligns the team around a shared vision.
Company milestones
Selected organisational, standards and research milestones.
- 2025
The Hainan Boao Lecheng Medical and Drug Administration approved Ciming Boao International Hospital to carry out Beike's “Human Umbilical Cord Mesenchymal Stem Cell Therapy Technology for Type 2 Diabetes” as a translational application project.
- 2024
Beike's “Human Umbilical Cord Mesenchymal Stem Cell Injection” for moderate-to-severe systemic lupus erythematosus received a Drug Clinical Trial Approval Notice from the NMPA's Center for Drug Evaluation; the CDMO laboratory at the Harbin Beike Cell Industry Base was launched; two co-drafted group standards were released (T/FDSA 0049-2024 on MSC exosomes, T/CRHA 041-2024 on human-derived cell storage services); a strategic cooperation agreement was signed with Sino Biological; named a “Top 100 Shenzhen Brand” for the second consecutive time.
- 2023
The national standard “Technical Specifications for the Design of Cell Culture Clean Rooms” (GB/T 42398-2023), in which Beike participated, was officially released; a second co-developed national standard, “Technical Specification for Cell Culture Operations in Cleanrooms and Controlled Environments” (GB/T 43459-2023), was announced in December.
- 2022
Approved to build the Shenzhen Academician (Expert) Workstation; introduced and deployed its first new fully-automatic cell intelligent-manufacturing system.
- 2021
Won the title of “Shenzhen Famous Brand.”
- 2020
MSC drug development for COVID-19 pneumonia approved as a key MoST project; UC-MSC clinical study approved by Guangdong's emergency special programme; issued two Shenzhen local transport standards (DB4403/T 120-2020 & 121-2020).
- 2019
Participated project on allogeneic MSCs for refractory lupus won the second prize of the National Technological Invention Award; reapproved as a Shenzhen Standardization Innovation Demonstration Base.
- 2018
Awarded “Model Enterprise for Synchronous Standardization and Innovation” in Shenzhen.
- 2017
Shenzhen local standard for comprehensive cell banks (SZDB/Z 266-2017) released; four autologous cell-storage systems at the Shenzhen Comprehensive Cell Bank passed AABB accreditation.
- 2016
Shenzhen local standard for cell preparation centers (SZDB/Z 188-2016) officially released.
- 2015
Shenzhen (Beike) Regional Cell Preparation Center approved; HQ and International Stem Cell R&D Base completed; clinical translation network established with 11 Shenzhen medical institutions.
- 2014
Shenzhen Development and Reform Commission approves Beike to establish the Shenzhen Comprehensive Cell Bank.
- 2013
Approved to establish a Shenzhen Postdoctoral Innovation and Practice Base; MSC injection for systemic lupus erythematosus listed as a major technical research project; cells from three batches across nine passages passed testing by the National Institutes for Food and Drug Control.
- 2011
Two stem cell technologies of Beike's Jiangsu Branch passed AABB certification.
- 2009
Shenzhen's Bio-Industry plan specifically calls for advancing Beike's stem-cell and regenerative-medicine industrialisation project.
- 2007
Beike's international activities and early patient-related work began receiving wider media attention. Historical reports of individual outcomes should not be interpreted as clinical evidence.
- 2006
BusinessWeek reported on Beike and Shenzhen's emerging role in cell-technology research.
- 2005
Shenzhen Beike Biotechnology Co., Ltd. was established.
Qualifications & patents
Credentials earned across two decades of cell-therapy work.
Company figures reported in January 2024 listed 207 patent applications in the cell field, including 162 authorised patents; more than 100 papers; and participation in more than 70 government-supported projects. These figures are dated and do not by themselves establish the current status or clinical validity of a product or programme.
National High-Tech Enterprise
Recognised under China's National High-Tech Enterprise programme for cell-therapy R&D.
AABB accreditation
Accreditation applies to the activities and facilities listed in the relevant accreditation record; it is not a product approval.
ISO 9001 / 14001 / 45001
Company-reported integrated management-system certification history as of January 2024; current scope should be verified.
ISO 27001
Information-security management system certification.
207 patents · 100+ papers
162 patents authorised and 100+ papers in authoritative journals as of January 2024.
Academician (Expert) Workstation
Approved Shenzhen Academician (Expert) Workstation in 2022.
AABB
AABB accreditation for specified cell-banking activities.
Beike reports that its Jiangsu operation obtained AABB accreditation in 2012 and that specified autologous cell-storage systems at the Shenzhen Comprehensive Cell Bank were accredited in 2017. Accreditation applies only to the scope and period recorded by AABB and should be verified before reliance.
